Serum omentin-1 levels in hypertensive patients

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Biomarkers

Background:

• Hypertension (HT) is associated with increased inflammation and endothelial dysfunction.
• Omentin-1, an adiponectin family member, possesses anti-inflammatory properties and its levels correlate inversely with obesity and insulin resistance.
• Serum omentin-1 is recognized as a biomarker for various conditions including cardiovascular disease, metabolic syndrome, and diabetes mellitus.

Purpose of the Study:

• To investigate and compare circulating omentin-1 levels in patients with essential hypertension versus healthy normotensive individuals.
• To assess potential differences in omentin-1 levels between stages of hypertension.

Main Methods:

• A comparative study involving newly diagnosed essential hypertension patients (n=61) and healthy normotensive controls (n=60).
• Hypertension patients were stratified into Stage 1 (n=31) and Stage 2 (n=30) subgroups.
• Serum omentin-1 concentrations were measured and compared between the groups.

Main Results:

• Serum omentin-1 levels were significantly lower in both Stage 1 (72.19 ± 54.33 ng/ml) and Stage 2 (62.45 ± 47.01 ng/ml) hypertensive subgroups compared to normotensive controls (147.84 ± 58.55 ng/ml).
• The difference in omentin-1 levels between hypertensive patients and controls was statistically significant (P < 0.001).

Conclusions:

• Patients with hypertension exhibit significantly reduced serum omentin-1 levels compared to normotensive individuals.
• Lower omentin-1 concentrations in hypertension may be linked to underlying endothelial dysfunction, inflammation, and potential renal injury.
• Omentin-1 warrants further investigation as a potential biomarker for hypertension and its associated pathophysiological processes.